Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.
Sirolimus (Rapamycin) is an FDA-approved medication which may improve the blood flow to the brain. The purpose of the clinical trial is to find out whether sirolimus can help improve blood flow and energy use in the brain in women ages 45 to 65 who have the ApoE4 gene, a gene which increases the risk of developing Alzheimer's disease later in life.
There will be two arms in this trail, a sirolimus arm and a placebo arm. A placebo is a pill that looks like the study drug, but it does not have any real medicine in it. Participants will be randomized to one arm or the other, but not to both arms. Three study visits over a 12-week period are required.
Participants will: (i) Complete some questionnaires about how well you think; (ii) Complete genetic testing for the ApoE4 gene; (iii) Have blood work, blood pressure and height and weight collected; (iv) Take either Sirolimus or a placebo daily, by mouth, for approximately 4 weeks; (v) Keep a diary of when the sirolimus or placebo is taken; (vi) Complete 2 Magnetic Resonance Imaging (MRI) exams
Inclusion Criteria:
Willing and able to provide informed consent
Sex assigned at birth: female
45-65 years old
Able to perform self-care and activities of daily living with no or minimal assistance
Post-menopausal status or use of highly effective contraception. Post-menopausal is defined as either
Body weight of ≥ 40 kg
Ability to effectively communicate with the investigator and comply with study requirements
Exclusion Criteria:
Diagnosis of mild cognitive impairment (MCI), dementia, or Alzheimer's disease
BMI ≥ 35 (based on MRI feasibility)
Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c ≥ 6.5%)
History of skin ulcers or poor wound healing
Current tobacco or illicit drug use or alcohol abuse (defined as ≥ 3 per day or ≥ 7 per week for women) (Per NIAAA guidelines)
Use of anti-platelet or anti-coagulant medications other than aspirin
Required use of medications that affect cytochrome P450 3A4 (CYP3A4) or alter cerebral blood flow (see Appendix 1 for tables of excluded medications)
Immunosuppressant therapy within the last year
Chemotherapy or radiation treatment within the last year
Current or chronic history of liver or kidney disease or known hepatic or biliary abnormalities
Untreated hypertriglyceridemia (fasting triglycerides < 300 mg/dl)
Current or chronic significant history of pulmonary disease
Chronic heart failure
Pregnancy or lactation
Recent history (past six months) of myocardial infarction, active coronary artery disease, intestinal disorders, stroke, or transient ischemic attack
Poorly controlled blood pressure (systolic BP > 160 or diastolic BP > 100 mmHg)
Active inflammatory, COVID-19, autoimmune, infectious, hepatic, gastrointestinal, malignant, and/or severe mental illness
History of, or MRI, or CT positive for, any space occupying brain lesion, including mass effect or abnormal intracranial pressure
Organ transplant recipients
History of Stroke
History of ruptured intracranial aneurysm
History of malignancy within the past 2 years, with the following exceptions:
History of epilepsy
umhsradstudycoordinators@health.missouri.edu573-884-5372
nbhtd@missouri.edu
This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults
Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography
Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
Rapamycin - Effects on Alzheimer's and Cognitive Health
The Role of Sirolimus in Preventing Functional Decline in Older Adults
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]
The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study